HAP1 Activators
HAP1 activators encompass a diverse array of chemical compounds that enhance the functional activity of HAP1 through distinct but often interrelated signaling pathways. Forskolin, Rolipram, IBMX, and 8-Br-cAMP all elevate intracellular cAMP levels, either by direct activation of adenylate cyclase or through inhibition of phosphodiesterases, which leads to an increase in PKA activity. PKA can then phosphorylate various substrates that regulate HAP1, thereby indirectly enhancing its function. Similarly, Epinephrine and Dopamine, by binding to their respective receptors, stimulate adenylate cyclase to increase cAMP and activate PKA, potentially influencing HAP1 activity through downstream phosphorylation events. L-DOPA is included as it is a precursor to dopamine, thus contributing to the dopaminergic signaling cascade that could indirectly augment HAP1 function.
Continuing with the theme of cAMP-mediated activation, PACAP, by directly stimulating adenylate cyclase, increases PKA activity, which may facilitate the enhancement of HAP1. Vardenafil and Zaprinast, as inhibitors of phosphodiesterase 5, lead to an upsurge in cAMP levels, thereby activating PKA and potentially promoting the phosphorylation of proteins thatinteract with HAP1. Cholera toxin, diverging from the phosphodiesterase inhibitors, irreversibly activates adenylate cyclase causing a sustained increase in cAMP and continuous PKA activation, which could lead to prolonged enhancement of HAP1 activity. Lastly, Anisomycin, though primarily known as a protein synthesis inhibitor, also activates stress-activated protein kinases, which can phosphorylate substrates that may interact with and augment the activity of HAP1, providing a stress response mechanism that could indirectly upregulate HAP1's function in the cell. Collectively, these HAP1 activators operate through a synergy of pathways that converge on the modulation of cAMP and PKA signaling, which is pivotal for the phosphorylation-dependent regulation of proteins affecting HAP1's activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin serves as an activator of adenylate cyclase, thus increasing cyclic AMP (cAMP) levels intracellularly. The rise in cAMP can lead to activation of protein kinase A (PKA), which may then phosphorylate proteins that interact with or regulate HAP1, enhancing HAP1 activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, preventing the breakdown of cAMP. Elevated cAMP levels can activate PKA, which can subsequently phosphorylate HAP1, leading to its increased activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP and activation of PKA. This may enhance HAP1 function through phosphorylation events. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromoadenosine 3',5'-cyclic monophosphate is a cAMP analog that resists degradation by phosphodiesterases, directly activating PKA. Active PKA can phosphorylate targets that modulate HAP1 activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine interacts with adrenergic receptors, leading to the activation of adenylate cyclase and an increase in cAMP levels. Through PKA activation, this can enhance the activity of HAP1. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine binds to its receptors, which can activate adenylate cyclase, increasing cAMP, and subsequently PKA activity. PKA can influence HAP1 activity through phosphorylation of HAP1 or related proteins. | ||||||
Levodopa | 59-92-7 | sc-205372 sc-205372A | 5 g 25 g | $54.00 $171.00 | 9 | |
Levodopa is a precursor of dopamine and can enhance dopaminergic signaling, potentially leading to increased cAMP and PKA activity, which may indirectly enhance HAP1 activity. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil is a phosphodiesterase-5 inhibitor leading to increased cAMP and subsequent PKA activity, which can enhance HAP1 function indirectly through phosphorylation pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5, increasing cAMP levels, thus activating PKA. PKA-mediated phosphorylation could enhance HAP1's activity. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor which can activate stress-activated protein kinases (SAPKs). These kinases can phosphorylate several substrates that might interact with and enhance HAP1 activity. | ||||||